Beneficial Effects of Omega-3 Fatty Acids on Low Density Lipoprotein Particle Size in Patients with Type 2 Diabetes Already under Statin Therapy
Diabetes & Metabolism Journal
; : 207-211, 2013.
Article
en En
| WPRIM
| ID: wpr-35730
Biblioteca responsable:
WPRO
ABSTRACT
Beyond statin therapy for reducing low density lipoprotein cholesterol (LDL-C), additional therapeutic strategies are required to achieve more optimal reduction in cardiovascular risk among diabetic patients with dyslipidemia. To evaluate the effects and the safety of combined treatment with omega-3 fatty acids and statin in dyslipidemic patients with type 2 diabetes, we conducted a randomized, open-label study in Korea. Patients with persistent hypertriglyceridemia (> or =200 mg/dL) while taking statin for at least 6 weeks were eligible. Fifty-one patients were randomized to receive either omega-3 fatty acid 4, 2 g, or no drug for 8 weeks while continuing statin therapy. After 8 weeks of treatment, the mean percentage change of low density lipoprotein (LDL) particle size and triglyceride (TG) level was greater in patients who were prescribed 4 g of omega-3 fatty acid with statin than in patients receiving statin monotherapy (2.8%+/-3.1% vs. 2.3%+/-3.6%, P=0.024; -41.0%+/-24.1% vs. -24.2%+/-31.9%, P=0.049). Coadministration of omega-3 fatty acids with statin increased LDL particle size and decreased TG level in dyslipidemic patients with type 2 diabetes. The therapy was well tolerated without significant adverse effects.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Tamaño de la Partícula
/
Hipertrigliceridemia
/
Ácidos Grasos Omega-3
/
Colesterol
/
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Diabetes Mellitus Tipo 2
/
Dislipidemias
/
Corea (Geográfico)
/
Lipoproteínas
/
LDL-Colesterol
Tipo de estudio:
Clinical_trials
Límite:
Humans
País/Región como asunto:
Asia
Idioma:
En
Revista:
Diabetes & Metabolism Journal
Año:
2013
Tipo del documento:
Article